Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR Study

Joint Bone Spine

Volumn 75, Issue 4, 2008, Pages 408-415

  Kobelt, Gisela ^a,b   Woronoff, Anne Sophie ^c   Richard, Brigitte ^b   Peeters, Pascale ^d   Sany, Jacques ^e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b European Health Economics ^*  (France)

^c ANDAR   (France)

^d IQVIA   (United States)

^e UNIV MONTPELLIER   (France)

Author keywords

Cost; France; Quality of life; Rheumatoid arthritis; Utility

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; ARTHRITIS; ARTICLE; COST UTILITY ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ECONOMIC EVALUATION; FEMALE; FRANCE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; QUALITY OF LIFE; RETIREMENT; RHEUMATOID ARTHRITIS;

AGED; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; EFFICIENCY; EMPLOYMENT; FEMALE; FRANCE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 46749114089     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.07.015     Document Type: Article

References (29)

1. Kobelt G. Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35 (2006) 415-425
2. Thompson M., Leighton-Read J., Hutchings C., et al. The cost effectiveness of auranofin. Results of a randomized clinical trial. J Rheumatol 15 (1988) 35-42
3. Kamal K.M., Madhavan S.S., Hornsby J.A.A., et al. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 73 (2006) 718-724
4. Kvien T. Epidemiology and burden of illness of rheumatoid arthritis (review). Pharmacoeconomics 1 Suppl (2004) 1-12
5. Rosery H., Bergemann R., and Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review. Pharmacoeconomics 23 (2005) 243-257
6. Rat A.C., and Boissier M.C. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71 (2004) 518-524
7. Cooper N. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39 (2000) 28-33
8. Gabriel S., Coyle D., and Moreland L. A clinical and economic review of disease modifying antirheumatic drugs. Pharmacoeconomics 19 (2001) 715-728
9. Drummond M.F., Barbieri M., and Wong J.B. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference?. Med Decis Making 25 (2005) 520-533
10. Bansback N.J., Regier D.A., Ara R., et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65 (2005) 473-496
11. Kobelt G., Lindgren P., Lindroth Y., et al. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 1169-1175
12. Huscher D., Merkesdal S., Thiele K., et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65 (2006) 1175-1183
13. Hulsemann J.L., Mittendorf T., Merkesdal S., et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis 64 (2005) 1456-1461
14. Kobelt G., Eberhardt K., Jönsson L., et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 42 (1999) 347-356
15. Kobelt G., Jönsson L., Lindgren P., et al. Modelling the progression of rheumatoid arthritis. A two-country model to estimate costs and consequences RA. Arthritis Rheum 46 (2002) 2310-2319
16. Lajas C., Abasolo L., Bellajdel B., et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49 (2003) 64-70
17. Pentek M., Kobelt G., Szekanecz Z., et al. Burden of illness, costs and outcomes of rheumatoid arthritis in Hungary. Value Health 8 (2005) A29
18. Hulsemann J.L., Ruof J., Zeidler H., et al. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 26 (2006) 704-711
19. Guillemin F., Durieux S., Daures J.P., et al. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 31 (2004) 1297-1304
20. Hurst N., Kind P., Ruta D., et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36 (1997) 551-559
21. Kobelt G., Lindgren P., Singh A., et al. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 64 (2005) 1174-1179
22. Fautrel B., Woronoff-Lemsi M.C., Ethgen M., et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Joint Bone Spine 72 (2005) 550-556
23. Fautrel B., Saraux A., Maillefert J.F., et al. Costs of workups for the diagnosis of early arthritis: results of a nationwide survey. Arthritis Rheum 51 (2004) 507-512
24. Kobelt G., Andlin-Sobocki P., and Maksymowych W.P. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 33 (2006) 289-295
25. Kobelt G., Berg J., Lindgren P., et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77 (2006) 918-926
26. EuroQol, Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
27. Dolan P., Gudex C., Kind P., and Williams A. A social tariff for EuroQol: results from a UK general population survey (1995), Centre for Health Economics, University of York, York Report No.: Discussion Paper 138
28. Kobelt G., Lindgren P., Smala A., et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2 (2001) 60-68
29. Merkesdal S., Ruof J., Huelsemann J.L., et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 53 (2005) 234-240